Substituted tricyclic heterocyclic compound as pharmaceutical for treatment or prevention of covid-19

Substituted tricyclic heterocyclic compounds with a unique structure address the limitations of existing COVID-19 treatments by offering potent antiviral activity and resistance to emerging strains, providing a promising therapeutic and prophylactic solution for COVID-19.

WO2024228401A1PCT designated stage expired Publication Date: 2024-11-07ALBIUS SCIENCES BETA PTE LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016900
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current COVID-19 treatment drugs, primarily small molecule inhibitors, face challenges with emerging resistant strains and limited mechanism of action, necessitating the development of novel compounds with distinct molecular structures for effective treatment and prevention.

Method used

Development of substituted tricyclic heterocyclic compounds with a unique molecular structure, represented by specific formulas, exhibiting potent antiviral activity and high selectivity, potentially effective against SARS-CoV-2 and resistant strains.

Benefits of technology

The compounds demonstrate significant antiviral activity, with an IC50 of 1.7 μM and a high selectivity index, indicating their potential as safe and effective therapeutic and prophylactic agents against COVID-19, including strains resistant to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024016900_07112024_PF_FP_ABST
    Figure JP2024016900_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a compound that is useful for treatment or prevention of infection with the novel coronavirus SARS-CoV-2. The present invention relates to a compound represented by formula (I) [where the ring A, R1, R7, R2, R4, X, Y, and Z are as defined in the specification], an enantiomer or pharmaceutically acceptable salt thereof, use of these compounds for the treatment or prevention of infection with the novel coronavirus SARS-CoV-2, and pharmaceutical compositions comprising these compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Substituted tricyclic heterocyclic compounds as medicines for the treatment or prevention of novel coronavirus infection

[0001] This patent application claims priority under the Paris Convention to and the benefit of Japanese Patent Application No. 2023-076174 (filed May 2, 2023), the entire contents of which are incorporated herein by reference.

[0002] The present invention generally relates to substituted tricyclic heterocyclic compounds as medicaments for the treatment and / or prevention of COVID-19 infection, and pharmaceutical compositions containing the same.

[0003] The SARS-CoV-2 novel coronavirus disease (COVID-19), which spread globally from the end of 2019, remains a pandemic as of February 2023, nearly three years after the outbreak. Although new treatments, including mRNA vaccines and other preventive drugs, have been developed, the number of newly diagnosed cases remains at around 2 million per day, with no end in sight (Non-Patent Document 1). Therefore, there is a high possibility that new SARS-CoV-2 mutant strains will emerge from infected individuals in the future, raising concerns about the emergence of resistant strains that evade existing vaccines and treatments. Furthermore, new pandemics are likely to emerge from zoonotic diseases such as coronaviruses and influenza viruses, and coronaviruses are ranked as a top candidate for the next pandemic pathogen (Non-Patent Document 2). There is a significant social demand for the development of novel coronavirus infection treatments with novel mechanisms of action and molecular structures that are effective against strains resistant to existing drugs.

[0004] As of February 2023, three types of drugs have been approved for the treatment of COVID-19: antivirals, neutralizing antibodies, and anti-inflammatory drugs. Among these, small molecule drugs that can be administered orally can generally be stored at room temperature and do not require injections, allowing for widespread global supply regardless of local transportation and medical infrastructure. Therefore, if small molecule drugs could be mass-produced safely and affordably, they could contribute to ending the pandemic. Three small molecule drugs have been approved overseas: remdesivir (1), molnupiravir (2), and nilmatrervir (3) / ritonavir (4). In Japan, ensitrervir (5) has also been approved.

[0005]

[0006] Remdesivir and molnupiravir are inhibitors of viral RNA-dependent RNA polymerase, and nilmatrervir and ensitrervir are inhibitors of viral 3C-like protease (Non-patent Document 3).

[0007] “Daily confirmed COVID-19 cases and deaths, World”. Published online at OurWorldInData.org. Retrieved from: 'https: / / ourworldindata.org / grapher / daily-covid-cases-deaths' [Online Resource] Zoeo L. Grange, Tracey Goldstein, Christine K. Johnson and Jonna AK Mazet, “Ranking the risk of animal-to-human spillover for newly discovered viruses” Proc. Natl. Acad. Sci. 2021, 118, e2002324118; 'https: / / doi.org / 10.1073 / pnas.2002324118'Renata Esposito, Davida Mirra, Liberata Sportiello, Giuseppe Spaziano, D'Agostino Bruno, “Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?”, Biomedicines 2022, 10, 2815; 'https: / / doi.org / 10.3390 / biomedicines10112815'

[0008] Since all of the above small molecule drugs are inhibitors of viral proteins, the emergence of resistant strains is expected, and therefore the development of candidate pharmaceutical compounds with different mechanisms of action and molecular structures is desired.

[0009] The present inventors have newly searched for a group of tricyclic heterocyclic compounds with molecular structures completely different from the above-mentioned small molecule drugs for the treatment of COVID-19, and selected from these compounds to have IC 50 = 1.7 μM potent antiviral activity and 235-fold more cytotoxicity / antiviral activity (CC 50 / I C 50We have discovered compounds that exhibit selectivity for the novel coronavirus. The compounds of the present invention for treating and / or preventing the novel coronavirus can be safe and highly active drugs for treating and / or preventing COVID-19. Furthermore, because they have a unique molecular structure not previously reported, they are likely to remain effective even if strains resistant to existing drugs emerge.

[0010] Therefore, the present invention includes the following aspects: <Compound> [1] Formula (I): wherein ring A is a group represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 together with the carbons to which they are attached are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, optionally substituted carbonyl, optionally substituted sulfonyl, or optionally substituted sulfinyl; X is hydrogen, hydroxy, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, Y is hydrogen or optionally substituted C1-6 alkyl, or X and Y together with adjacent carbon atoms form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring;wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] a compound represented by the formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof;

[0011] [2] Formula (I): wherein ring A is a group represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7, together with the carbons to which they are attached, are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; X is hydrogen or hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y, together with the adjacent carbon atoms, form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring; wherein the substituents in "optionally substituted" are selected from the following: It is hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] The compound according to [1], its enantiomer, or a pharmaceutically acceptable salt thereof, which is represented by the formula:

[0012] [3] Formula (II): [wherein ring A, R1 and R7, R2 and R4, X and Y, and Z are as defined above], an enantiomer thereof, or a pharmaceutically acceptable salt thereof according to [1].

[0013] [4] Ring A is a group represented by the formula: [wherein R3, R5, R6 and R8, Y, T, U, V and W are as defined above; and Q is hydrogen, hydroxy, halogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylamino, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl]. A compound according to [1] or [2], an enantiomer thereof, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

[0014] [5] Ring A is a group represented by the formula: [wherein R3, R5, R6 and Y are as defined above; R is hydrogen, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl]; and X is hydroxy. The compound according to [4], its enantiomer, or a pharmaceutically acceptable salt thereof.

[0015] [6] The compound according to [1], its enantiomer, or its pharmaceutically acceptable salt, wherein R2 and R4 are the same group.

[0016] <Preferred Compound> [7] Formula (III): wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 are joined together with the carbons to which they are attached to form a bridge to form a C3-6 spiro ring; R2 and R4 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5 and R6 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy, X is hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y together with the adjacent carbon atom form a double bond; wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] The compound according to [1], its enantiomer, or a pharmaceutically acceptable salt thereof,

[0017] [8] Either R1 or R7 is hydrogen, and the other is a group represented by the formula: or R1 and R7 together are selected from groups of the formula: and the triazacyclohexane ring substituted with R2, R4 and X forms a spiro ring represented by the formula: The compound according to [7], its enantiomer, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group represented by the formula:

[0018] [9] The compound according to [7], its enantiomer, or its pharmaceutically acceptable salt, wherein X and Y together with the adjacent carbon atoms form a double bond.

[0019]

[10] Formula: The compound according to [9], an enantiomer thereof, or a pharmaceutically acceptable salt thereof, which is a compound according to any one of the following:

[0020]

[11] R3 is a group represented by the formula: [wherein each R9 is independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group, or when there are two R9, they are bridged together with the nitrogen to which they are attached to form an optionally substituted 3- to 6-membered ring.] The compound according to [7], its enantiomer, or a pharmaceutically acceptable salt thereof, wherein R9 is selected from the group represented by the formula:

[0021] [11-2] R3 is a group represented by the formula: [wherein R9, together with the nitrogen to which they are attached, form a bridge to form an optionally substituted 5-membered ring], the compound according to [11-2], its enantiomer, or a pharmaceutically acceptable salt thereof.

[0022] [11-3] Formula: is an optionally substituted 5-membered ring of the formula: [wherein X is hydrogen, hydroxy, halogen, cyano, carbamoyl, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 alkylamino], an enantiomer thereof, or a pharmaceutically acceptable salt thereof according to [11-2].

[0023]

[12] R3 is a group represented by the formula: [wherein each R9 independently represents hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group.] The compound according to

[11] , its enantiomer, or a pharmaceutically acceptable salt thereof,

[0024]

[13] R3 is a group represented by the formula: The compound according to

[12] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a group represented by the formula:

[0025]

[14] The compound according to [7], its enantiomer, or its pharmaceutically acceptable salt, wherein R2 and R4 are the same group.

[0026]

[15] The compound according to [7], its enantiomer, or its pharmaceutically acceptable salt, wherein X and Y together with the adjacent carbon atoms form a double bond.

[0027] <Pharmaceutical Composition>

[16] A pharmaceutical composition comprising the compound according to any one of [1] to

[15] , its enantiomer, or a pharmaceutically acceptable salt thereof.

[0028]

[17] The pharmaceutical composition described in

[16] for treating or preventing novel coronavirus infection caused by SARS-CoV-2.

[0029] According to the present invention, novel coronavirus infection caused by SARS-CoV-2 can be effectively treated or prevented.

[0030] In one aspect, the present invention provides a compound of formula (I): wherein ring A is a group represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl;

[0031] R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, optionally substituted carbonyl, optionally substituted sulfonyl, or optionally substituted sulfinyl, preferably R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl;

[0032] X is hydrogen, hydroxy, optionally substituted C1-6 alkyl or optionally substituted C1-6 alkoxy, preferably X is hydrogen or hydroxy, Y is hydrogen or optionally substituted C1-6 alkyl, preferably Y is hydrogen or optionally substituted methyl, or X and Y together with the adjacent carbon atoms form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl or optionally substituted C1-6 alkoxy, T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring; wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.], an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0033] In this aspect, preferred compounds of the invention are those of formula (II): [wherein ring A, R1 and R7, R2 and R4, X and Y, and Z are as defined above], or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0034] In this aspect, preferred compounds of the invention are those in which ring A is of the formula: [wherein R3, R5, R6 and R8, Y, T, U, V and W are as defined above; and Q is hydrogen, hydroxy, halogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylamino, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl], or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, of the compound of the present invention.

[0035] In this aspect, further preferred compounds of the invention are those in which ring A is of the formula: wherein R, R, R and Y are as defined above; R is hydrogen, optionally substituted carbonyl, optionally substituted C alkyl, optionally substituted C aryl, or optionally substituted C heteroaryl; and X is hydroxy.

[0036] In this aspect, further preferred compounds of the invention are those compounds of the invention, their enantiomers, or pharmaceutically acceptable salts thereof, wherein R2 and R4 are the same group.

[0037] The compound represented by formula (I) specifically has the following formula: It is a compound represented by any one of the following formulas:

[0038] In this aspect, preferred compounds of the present invention are of the formula: Formula (III): wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 are joined together with the carbons to which they are attached to form a bridged C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5 and R6 are each independently hydrogen, hydroxy, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, X is hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y are joined together with the adjacent carbon atoms to form a double bond; wherein the substituents in "optionally substituted" are selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C alkyl, optionally substituted C alkoxy, optionally substituted C aryl, optionally substituted C heteroaryl, or a protecting group.], an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0039] In this embodiment, a further preferred compound of the present invention is a compound of formula (III) in which either R1 or R7 is hydrogen and the other is a compound of formula: or R1 and R7 together represent a group of the formula: and the triazacyclohexane ring substituted with R2, R4 and X forms a spiro ring represented by the formula: The compound of the present invention is selected from the group consisting of:

[0040] In such an embodiment, even more preferred compounds of the invention are of the formula: The compound of the present invention is a compound according to any one of the following formulas, an enantiomer thereof, or a pharmaceutically acceptable salt thereof:

[0041] In this aspect, another embodiment of the present invention is a compound of formula (III) wherein R3 is of the formula: [wherein each R9 is independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group, or when there are two R9, they are bridged together with the nitrogen to which they are attached to form an optionally substituted 3- to 6-membered ring.] Specifically, the compound of the present invention, its enantiomer, or a pharmaceutically acceptable salt thereof is selected from the group represented by the formula: [wherein R9 are bridged together with the nitrogen to which they are attached to form an optionally substituted 5-membered ring], and preferably a group represented by the formula: is an optionally substituted 5-membered ring of the formula: [wherein X is hydrogen, hydroxy, halogen, cyano, carbamoyl, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 alkylamino], an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0042] Preferably, the formula: and more preferably selected from groups represented by the formula: The compound of the present invention is a group represented by the formula:

[0043] In this embodiment, preferred compounds of the present invention are compounds of the present invention, their enantiomers, or pharmaceutically acceptable salts thereof, in which R2 and R4 are the same group in formulas (I), (II), and (III).

[0044] In such an embodiment, preferred compounds of the present invention are compounds of the present invention, their enantiomers, or pharmaceutically acceptable salts thereof, wherein X and Y together with adjacent carbon atoms form a double bond in formula (I), (II), and (III).

[0045] The terms used herein are used in the sense commonly used in the art unless otherwise specified. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.

[0046] <Definitions> In this specification, the term "group" means a monovalent group unless otherwise specified. Examples of non-monovalent groups include alkylene groups (divalent). In addition, in the following explanations of substituents, etc., the term "group" may be omitted in some cases.

[0047] In this specification, when defined as "optionally substituted" or "substituted," the number of substituents is not particularly limited as long as substitution is possible, and is one or more. Furthermore, unless otherwise specified, the description of each substituent also applies when that substituent is a part of or a substituent for another substituent.

[0048] In the present specification, any part of a group modified with "optionally substituted" or "substituted" may be substituted. For example, in "optionally substituted arylalkyl" and "substituted arylalkyl," the aryl part may be substituted, the alkyl part may be substituted, or both the aryl part and the alkyl part may be substituted.

[0049] In this specification, "C1-6" means that the number of carbon atoms is 1 to 6. The same applies to other numbers, for example, "C1-4" means that the number of carbon atoms is 1 to 4, and "C1-3" means that the number of carbon atoms is 1 to 3.

[0050] As used herein, the term "heteroatom" refers to an atom other than carbon or hydrogen atoms, such as an oxygen atom, nitrogen atom, or sulfur atom.

[0051] As used herein, "hydroxy" refers to the monovalent radical -OH. This group may also be referred to as a "hydroxy group" or "hydroxy."

[0052] As used herein, "halogen" refers to an atom belonging to the halogen group, such as a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. A fluorine atom or a chlorine atom is preferred. A fluorine atom is more preferred. "Halogen" may also be referred to as "halogen atom" or "halo".

[0053] As used herein, "carboxy" refers to the monovalent radical -COOH. This group is also called a "carboxy group," "carboxyl," "carboxylic acid group," or "carboxylic acid group."

[0054] As used herein, "cyano" is the monovalent radical -CN.

[0055] As used herein, "amino" refers to the monovalent radical -NH. This group may also be referred to as an "amino group."

[0056] As used herein, "alkyl" refers to a linear or branched saturated aliphatic hydrocarbon group. "C1-6 alkyl" refers to an alkyl group having 1 to 6 carbon atoms, with preferred examples including "C1-4 alkyl," more preferably "C1-3 alkyl," and even more preferably "C1-2 alkyl." Specific examples of "C1-4 alkyl" include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, etc. Specific examples of "C1-6 alkyl" include, but are not limited to, C1-4 alkyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 1,2-dimethylpropyl, n-hexyl, etc.

[0057] As used herein, "alkenyl" refers to a straight-chain or branched aliphatic hydrocarbon group having a double bond. "C2-6 alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms, with preferred examples including "C2-4 alkenyl," and more preferably "C2-3 alkenyl." Specific examples of "C2-4 alkenyl" include vinyl, propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, and the like. Specific examples of "C2-6 alkenyl" include, but are not limited to, C2-4 alkenyl, n-pentenyl, isopentenyl, neopentenyl, 1,2-dimethylpropenyl, n-hexenyl, and the like.

[0058] As used herein, "alkynyl" refers to a linear or branched aliphatic hydrocarbon group having a triple bond. "C2-6 alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms, and preferred examples include "C2-4 alkynyl," more preferably "C2-3 alkynyl." Specific examples of "C2-4 alkynyl" include ethynyl, propynyl, isopropynyl, n-butynyl, isobutynyl, sec-butynyl, etc. Specific examples of "C2-6 alkynyl" include, but are not limited to, C2-4 alkynyl, n-pentynyl, isopentynyl, neopentynyl, 1,2-dimethylpropynyl, n-hexynyl, etc.

[0059] As used herein, "aryl" refers to a monovalent group of a monocyclic or bicyclic aromatic hydrocarbon ring, and "C6-10 aryl" refers to an aryl group having 6 to 10 carbon atoms. Examples of "aryl" include, but are not limited to, C6 aryl, C10 aryl, etc. Specific examples of C6 aryl include, but are not limited to, phenyl, etc. Specific examples of C10 aryl include, but are not limited to, 1-naphthyl, 2-naphthyl, etc.

[0060] As used herein, "heteroaryl" refers to a monovalent monocyclic or bicyclic aromatic heterocyclic group containing 1 to 4 identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms.

[0061] As used herein, "C5-10 heteroaryl" refers to a monovalent monocyclic or bicyclic aromatic heterocyclic group consisting of 5 to 10 atoms containing 1 to 4 identical or different heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur atoms. Specific examples of "C5-10 heteroaryl" include, but are not limited to, pyrrolidyl, imidazole, oxadiazole, triazole, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, naphthyridinyl, quinoxalinyl, cinnolinyl, quinazolinyl, phthalazinyl, imidazopyridyl, imidazothiazolyl, imidazooxazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, pyrrolopyridyl, thienopyridyl, furopyridyl, benzothiadiazolyl, benzoxadiazolyl, pyridopyrimidinyl, benzofuryl, benzothienyl, benzo[1,3]dioxole, thienofuryl, chromenyl, chromanyl, coumarinyl, quinolonyl, and the like.

[0062] As used herein, "alkoxy" refers to a monovalent -O-alkyl group. Preferred examples of alkoxy include C1-6 alkoxy (i.e., C1-6 alkyl-O-), C1-4 alkoxy (i.e., C1-4 alkyl-O-), and the like. Specific examples of C1-4 alkoxy include methoxy (CHO-), ethoxy (CHCHO-), n-propoxy (CH(CH)O-), isopropoxy ((CH)CHO-), n-butoxy (CH(CH)O-), isobutoxy ((CH)CHCHO-), tert-butoxy ((CH)CO-), sec-butoxy (CHCHCH(CH)O-), and the like. Specific examples of C1-6 alkoxy include, but are not limited to, C1-4 alkoxy, n-pentyloxy (CH3(CH2)4O-), isopentyloxy ((CH3)2CHCH2CH2O-), neopentyloxy ((CH3)3CCH2O-), tert-pentyloxy (CH3CH2C(CH3)2O-), 1,2-dimethylpropoxy (CH3CH(CH3)CH(CH3)O-), and the like.

[0063] As used herein, "optionally substituted carbonyl" refers to "substituted carbonyl" and "substituted carbonyl," "unsubstituted carbonyl" refers to a carboxylic acid group, and "substituted carbonyl" refers to an ester of carboxy or its amide, a hydrocarbonyl group, an optionally substituted lower alkylcarbonyl group, an optionally substituted arylcarbonyl group, etc.

[0064] For example, "alkylcarbonyl" is exemplified, which is a monovalent group of -C(=O)-alkyl. A preferred example of alkylcarbonyl is C1-6 alkylcarbonyl. A specific example of C1-6 alkylcarbonyl is acetyl (CH 3 C(=O)-), n-propanoyl(CH 3 CH 2 C(=O)-), n-butanoyl (CH 3 CH 2 CH 2 C(=O)-), n-pentanoyl(CH 3 (CH 2 ) 3 C(=O)-), n-hexanoyl (CH 3 (CH 2 ) 4 C(=O)-), n-heptanoyl (CH 3 (CH 2 ) 5 Examples include, but are not limited to, C(=O)-).

[0065] Further examples include "alkoxycarbonyl," which is a monovalent radical of -C(=O)-O-alkyl. Examples of alkoxycarbonyl include, but are not limited to, C1-6 alkoxycarbonyl, preferably C1-4 alkoxycarbonyl. Specific examples of C1-4 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, and the like. Specific examples of C1-6 alkoxycarbonyl include, but are not limited to, C1-4 alkoxycarbonyl, n-pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert-pentyloxycarbonyl, 1,2-dimethylpropyloxycarbonyl, n-hexyloxycarbonyl, and the like.

[0066] As used herein, "arylcarbonyl" refers to a monovalent group of -C(=O)-aryl. Preferred examples of arylcarbonyl include C6-10 arylcarbonyl. Specific examples of C6-10 arylcarbonyl include, but are not limited to, benzoyl (i.e., phenyl-C(=O)-), 1-naphthylcarbonyl, 2-naphthylcarbonyl, and the like.

[0067] Amides included in the "substituted carbonyl" include all substituted amides represented by R10R11NC=O (wherein R10 and R11 are each independently an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, or an optionally substituted C5-10 heteroaryl), including H2NC=O. Furthermore, amides also include imide structures such as R12(C=O)NH(C=O) (wherein R12 is an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, or an optionally substituted C5-10 heteroaryl) which further have an acyl group as a substituent.

[0068] As used herein, “optionally substituted sulfonyl” means “substituted sulfonyl” and “substituted sulfonyl.” “Substituted sulfonyl” means an ester of a sulfonic acid group or an amide thereof, a hydrosulfonyl group, an optionally substituted lower alkylsulfonyl group, an optionally substituted arylsulfonyl group, etc.

[0069] For example, "C alkylsulfonyl" refers to a sulfonyl group substituted with the above-mentioned "C alkyl". As "C alkylsulfonyl", "C alkylsulfonyl" is preferred. Specific examples of "C alkylsulfonyl" include, but are not limited to, methylsulfonyl, propylsulfonyl, butylsulfonyl, etc.

[0070] As used herein, “optionally substituted sulfinyl” means “substituted sulfinyl” and “substituted sulfinyl.” “Substituted sulfinyl” means an ester of a sulfinic acid group or an amide thereof, a hydrosulfinyl group, an optionally substituted lower alkylsulfinyl group, an optionally substituted arylsulfinyl group, etc.

[0071] A "protecting group" refers to a group of atoms that, when attached to a reactive functional group in a molecule, masks, reduces, or prevents the reactivity of the functional group. Typically, a protecting group can be selectively removed during a synthetic process, if desired. Examples of protecting groups can be found in Peter GM Wuts, "Greene's Protective Groups in Organic Synthesis", 5th Ed., John Wiley & Sons, Inc., Hoboken, New Jersey (2014) and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8, John Wiley & Sons, NY, etc. As used herein, a "protecting group" may fall within the definition of substituent α. Representative nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilylethanesulfonyl ("TES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), and nitro-veratryloxycarbonyl ("NVOC"). Representative hydroxyl protecting groups include, but are not limited to, those in which the hydroxyl group is acylated (esterified) or alkylated, such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS, triethylsilyl, t-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS)), alkylarylsilyl ethers (e.g., t-butyldiphenylsilyl (TBDPS)), triarylsilyl ethers (e.g., triphenylsilyl), glycol ethers (e.g., ethylene glycol ether, propylene glycol ether, etc.), and allyl ethers.

[0072] The compounds of the present invention exist in the form of stereoisomers such as tautomers and geometric isomers, and optical isomers, depending on the type of substituents, and the present invention includes all of these, as well as mixtures thereof. That is, when the compounds of the present invention have one or more asymmetric carbon atoms, diastereomers and optical isomers exist, and mixtures of these diastereomers and optical isomers, as well as isolated forms thereof, are also included in the compounds of the present invention.

[0073] In other embodiments, the present invention includes various hydrates, solvates and crystalline polymorphs.

[0074] Furthermore, as another embodiment, the present invention also includes prodrugs corresponding to the compounds of the present invention. In the present invention, a prodrug refers to a derivative that is hydrolyzed by acid or enzymatic decomposition in vivo to yield a compound represented by formula (I). For example, when a compound represented by formula (I) has a hydroxyl, amino, or carboxyl group, these groups can be modified using conventional methods to produce a prodrug. Prodrug technology is described, for example, in C.G. Wermuth, "The Practice of Medicinal Chemistry," 4th Ed., Academic Press, (2015), Chapter 28. For example, compounds having a carboxyl group include compounds in which the carboxyl group is an alkoxycarbonyl group, an alkylthiocarbonyl group, or an alkylaminocarbonyl group. For example, compounds having an amino group include compounds in which the amino group is substituted with an alkanoyl group to form an alkanoylamino group, compounds in which the amino group is substituted with an alkoxycarbonyl group to form an alkoxycarbonylamino group, compounds in which the amino group is substituted with an alkoxycarbonyl group to form an alkanoyloxymethylamino group, or compounds in which the amino group is hydroxylamine. Furthermore, for example, in the case of a compound having a hydroxyl, the hydroxyl may be substituted with the above-mentioned alkanoyl group to form an alkanoyloxy group, a phosphate ester, or an alkanoyloxymethyloxy group.

[0075] As used herein, the term "pharmaceutically acceptable salt" refers to an acid addition salt and a base addition salt that are acceptable for pharmaceutically use. Specific examples of "pharmaceutically acceptable salts" include acetate, propionate, butyrate, formate, trifluoroacetate, maleate, fumarate, tartrate, citrate, stearate, succinate, ethylsuccinate, malonate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, benzenesulfonate, paratoluenesulfonate (tosylate), lauryl sulfate, malate, ascorbate, mandelate, saccharate, xinafoate, pamoate, ketone ... Examples of the salts include, but are not limited to, acid addition salts such as arsenate, adipate, cysteine ​​salt, N-acetylcysteine ​​salt, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, acrylic acid polymer salt, and carboxyvinyl polymer; inorganic base addition salts such as lithium salt, sodium salt, potassium salt, and calcium salt; organic base addition salts such as morpholine and piperidine; and addition salts with amino acids such as aspartic acid and glutamic acid.

[0076] <Method for Producing the Compound of the Present Invention> General methods for producing the compound of the present invention will be explained below with examples, but the present invention is not limited to these.

[0077] The compounds of the present invention can be produced by the production methods described below. These production methods can be appropriately improved based on the knowledge of those skilled in organic synthetic chemistry. In the production methods described below, the compounds used as raw materials may be used in the form of salts, as long as they do not interfere with the reaction.

[0078] In the following production methods, even if the use of a protecting group is not specifically specified, if any functional group other than the reactive site changes under the reaction conditions or if the reaction is unsuitable for post-reaction treatment, the target compound can be obtained by protecting the functional group other than the reactive site as necessary and deprotecting it after the reaction or after a series of reactions. Protecting groups used in these processes include conventional protecting groups described in literature (Peter GM Wuts, "Greene's Protective Groups in Organic Synthesis," 5th Ed., John Wiley & Sons, Inc., Hoboken, New Jersey (2014)). The introduction and removal of protecting groups can be carried out by methods commonly used in organic synthetic chemistry (e.g., methods described in the above literature) or methods similar thereto.

[0079] The starting materials and intermediates in the following production methods are commercially available or can be obtained by synthesis from known compounds according to known methods or methods described in known literature. Furthermore, salts of these starting materials and intermediates may be used as long as they do not interfere with the reaction.

[0080] The intermediates and target compounds in the following production methods can be converted into other compounds included in the present invention by appropriately converting their functional groups. The conversion of functional groups can be carried out by a method commonly used in organic synthetic chemistry (e.g., the method described in R.C. Larock, "Comprehensive Organic Transformations," 2nd Ed., John Wiley and Sons, Inc., New York (1999)) or a method similar thereto.

[0081] In the production methods described below, the inert solvent means a solvent that does not react with the raw materials, reagents, bases, acids, catalysts, ligands, etc. used in the reaction (hereinafter, these may be referred to as "raw materials, etc. used in the reaction"). Even if the solvent used in each step reacts with the raw materials, etc. used in the reaction, it can be used as an inert solvent as long as the target reaction proceeds and the target compound is obtained.

[0082] The preparation of the compounds of the present invention is based on the formation of a piperazine skeleton followed by a reaction to form a triazadione skeleton.

[0083] The starting carboxylate compound is commercially available.

[0084] Synthesis of substituted tricyclic heterocycles [wherein R1 to R7 are as defined above, n is an integer of 0, 1 or 2, and P is a protecting group]

[0085] Step 1: Formation of Piperazine Skeleton Step 1 is a condensation reaction to introduce an amino acid structure, followed by deprotection of the amino group and subsequent cyclization to form the piperazine skeleton. This deprotection reaction is well known to those skilled in the art, and involves de-tert-butoxycarbonylation and de-9-fluorenylmethyloxycarbonylation.

[0086] Step 2: Formation of Triazadione Skeleton Step 2 is a reaction to form a triazadione skeleton by reaction with an isocyanate.

[0087] Pharmaceutical Compositions In one aspect, the compounds of the present invention are compounds having antiviral activity against the SARS-CoV-2 novel coronavirus. Specifically, the compounds of the present invention enable the treatment or prevention of SARS-CoV-2 novel coronavirus infection. Accordingly, in another aspect, the present invention provides a pharmaceutical composition, specifically a pharmaceutical composition for treating or preventing SARS-CoV-2 novel coronavirus infection, containing the compound of the present invention, an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0088] As used herein, "treatment" means a method or process intended to (1) delay or prevent the onset of a disease or condition; (2) slow or halt the progression, worsening, or deterioration of the symptoms of a disease or condition; (3) bring about the amelioration of the symptoms of a disease or condition; or (4) cure a disease or condition. Treatment may be administered prior to the onset of a disease or condition as a preventative measure, or alternatively, treatment may be administered after the onset of the disease.

[0089] In the present invention, "prevention" means preventing the onset of novel coronavirus infection caused by SARS-CoV-2.

[0090] In the present invention, the pharmaceutical composition generally means an agent for treating, managing or preventing a disease or pathological condition, or for testing or diagnosing the disease or pathological condition.

[0091] In one embodiment, the compound of the present invention can be administered orally or parenterally, either directly or in the form of a formulation, medicament, or pharmaceutical composition using an appropriate dosage form. Specific examples of these dosage forms include, but are not limited to, tablets, capsules, powders, granules, liquids, suspensions, injections, patches, and poultices. These formulations can be prepared by known methods using additives commonly used as pharmaceutical additives.

[0092] Depending on the purpose, these additives may include excipients, disintegrants, binders, fluidizing agents, lubricants, coating agents, solubilizers, solubilizers, thickeners, dispersants, stabilizers, sweeteners, flavors, etc. Specific examples of these additives include, but are not limited to, lactose, mannitol, crystalline cellulose, low-substituted hydroxypropyl cellulose, corn starch, partially pregelatinized starch, carmellose calcium, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, propylene glycol, titanium oxide, talc, etc.

[0093] The dose of the compound of the present invention is appropriately selected depending on the subject to be administered, the administration route, the disease, the age, weight, and symptoms of the subject. For example, in the case of oral administration, the lower limit is 0.01 mg (preferably 100 mg) and the upper limit is 10,000 mg (preferably 6,000 mg) per day for an adult, and this amount can be administered once a day or in divided doses.

[0094] In another aspect, the present invention relates to a method for treating or preventing SARS-CoV-2 novel coronavirus infection, the method comprising administering a compound of the present invention, its enantiomer, or a pharmaceutically acceptable salt thereof to a subject in need of such treatment, preferably a method comprising administering an effective amount of a compound of the present invention, its enantiomer, or a pharmaceutically acceptable salt thereof to such a subject. Furthermore, in another aspect, the present invention relates to a compound of the present invention, its enantiomer, or a pharmaceutically acceptable salt thereof for treating or preventing SARS-CoV-2 novel coronavirus infection. In yet another aspect, the present invention relates to use of a compound of the present invention, its enantiomer, or a pharmaceutically acceptable salt thereof for manufacturing a medicament for treating or preventing SARS-CoV-2 novel coronavirus infection.

[0095] References, such as patent literature and non-patent literature, such as patents or patent applications, cited in this specification are incorporated herein by reference to the same extent as if each were specifically disclosed in its entirety.

[0096] As described above, the preferred embodiments of the present invention have been described to facilitate understanding of the invention. Hereinafter, the present invention will be described in more detail based on Production Examples and Examples. However, it should be noted that the above description and the following Examples are merely illustrative and do not limit the scope of the present invention.

[0097] Production Example 1 (3R,6S,8aR)-3-benzyl-1,4-dioxooctahydropyrrolo[1,2-a]pyrazine-6-carboxylate 1-1

[0098] N-Fmoc-D-phenylalanine (518 mg, 1.31 mmol) was dissolved in dichloromethane (5.96 ml) in a 25 ml eggplant-shaped flask, followed by HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) (544 mg, 1.43 mmol), 2,5-diethyl-(2R,5S)-pyrrolidine-2,5-dicarboxylate hydrochloride (300 mg, 1.19 mmol), and finally diisopropylethylamine (0.830 ml, 4.77 mmol). The mixture was stirred at room temperature under a nitrogen atmosphere for 1.5 hours. The stir bar was removed and the solvent was evaporated. The residue was purified using a silica gel column Q-Pack SI30 size 60 (hexane:ethyl acetate = 50:50). After evaporation, the intermediate condensation product (669 mg, 1.14 mmol) was obtained. This was dissolved in dichloromethane (5.96 ml), piperidine (0.933 ml, 9.15 mmol) was added, and the mixture was stirred at room temperature for 14 hours. After evaporation, the solvent was evaporated and the resulting residue was purified using a silica gel column Q-Pack SI30 size 60 (chloroform:methanol = 100:0 to 97:3). After evaporation, the solvent was evaporated and the desired compound 1-1 (white amorphous solid) (313 mg, 0.989 mmol, 83% (after two steps)) was obtained.

[0099] Preparation Examples 2-15 Fourteen compounds shown in Table 1 were synthesized under the same reaction conditions as in Preparation Example 1, except that various amine starting materials were used in place of the amine starting material, 2,5-diethyl-(2R,5S)-pyrrolidine-2,5-dicarboxylate hydrochloride, and various carboxylic acid starting materials were used in place of the carboxylic acid starting material, N-Fmoc-D-phenylalanine.

[0100]

[0101]

[0102] Example 1 Ethyl (6R,9S,11aR,11bR)-1,3,6-tribenzyl-11b-hydroxy-2,4,7-trioxodecahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxylate 1A and Ethyl (6R,9S)-1,3,6-tribenzyl-2,4,7-trioxo-1,3,4,6,7,9,10,11-octahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxylate 1B

[0103] Compound 1-1 (30.0 mg, 94.8 μmol) prepared in Preparation Example 1 was added to a 10 ml eggplant-shaped flask and dissolved in tetrahydrofuran (2.37 ml). Subsequently, benzyl isocyanate (35.8 μl, 0.284 mmol) and 60% sodium hydride in oil (34.1 mg, 0.854 mmol) were added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 20 minutes. The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. After evaporation of the solvent, the residue was purified using a silica gel column, Q-Pack SI30, size 10 (hexane:ethyl acetate = 50:50). After evaporation of the solvent, 9.3 mg (16.0 μmol, 33%) of the desired compound 1A (white amorphous solid) and 6.1 mg (10.8 μmol, 11%) of its dehydrated compound 1B (white amorphous solid) were obtained.

[0104] Example 2-14 Under the same reaction conditions as in Example 1, 15 compounds shown in Table 2 were synthesized by using compounds 2-1 to 15-1 instead of the starting compound 1-1.

[0105]

[0106]

[0107] Examples 15-17 Three compounds shown in Table 3 were synthesized under the same reaction conditions as in Example 1, except that various isocyanates were used in place of benzyl isocyanate.

[0108]

[0109] Example 18 (6R,9S,11aR,11bR)-1,3,6-tribenzyl-11b-hydroxy-N-(naphthalen-2-ylmethyl)-2,4,7-trioxohydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 1D

[0110] 18-1: (6R,9S,11aR,11bR)-1,3,6-tribenzyl-11b-hydroxy-2,4,7-trioxohydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxylic acid 1C. Compound 1A (70 mg, 0.120 mmol) prepared in Example 1 was added to a 25 mL eggplant-shaped flask and dissolved in tetrahydrofuran (1.27 mL), methanol (1.92 mL), and water (0.632 mL). Lithium hydroxide (126 mg, 3.00 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was quenched with 1 M aqueous hydrochloric acid, extracted with ethyl acetate, and the solvent was evaporated to afford 63.9 mg (0.115 μmol, 96%) of the desired compound 1C (white solid).

[0111] 18-2: Compound 1D. Next, compound 1C (63.9 mg, 0.115 mmol) was added to a 10 ml eggplant-shaped flask with dichloromethane (3.84 ml), followed by HATU (87.6 mg, 0.230 mmol), 1-(2-naphthyl)methanamine (38.1 mg, 0.230 mmol), and finally diisopropylethylamine (0.120 ml, 0.691 mmol). The mixture was stirred at room temperature under a nitrogen atmosphere for 1.5 hours. The stir bar was removed and the solvent was evaporated. Water was added and the mixture was extracted with ethyl acetate. The residue was purified using a silica gel column, Q-Pack SI30, size 20 (hexane:ethyl acetate = 17:83). After evaporation of the solvent, 73.1 mg (0.105 mmol, 91%) of the desired compound 1D (white solid) was obtained.

[0112] Examples 19-27 Under the same reaction conditions as in Example 18, the 10 compounds shown in Table 4 were synthesized by using compounds 2A to 8A, 17A, and 18A instead of the starting compound 1A.

[0113]

[0114]

[0115] Example 28 (6R,9S)-6-Benzyl-N-(naphthalen-2-ylmethyl)-2,4,7-trioxo-1,3-diphenyl-1,3,4,6,7,9,10,11-octahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 16E

[0116] 28-1: (6R,9S)-6-Benzyl-11b-2,4,7-trioxo-1,3,4,6,7,9,10,11-octahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxylic acid 16C. Compound 16B (3.5 mg, 6.5 μmol) prepared in Example 15 was added to a 4 mL vial and dissolved in tetrahydrofuran (0.069 mL), methanol (0.104 mL), and water (0.034 mL). Lithium hydroxide (6.8 mg, 0.163 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was stopped with 1 M aqueous hydrochloric acid, and the mixture was extracted with ethyl acetate. The solvent was then evaporated to give 3.0 mg (5.9 μmol, 91%) of the desired compound 16C (white solid).

[0117] 28-2: Compound 16E. Next, compound 16C (3.0 mg, 5.9 μmol) in a 4 mL vial was added to dichloromethane (0.295 mL), followed by HATU (6.7 mg, 18 μmol), 1-(2-naphthyl)methanamine (2.9 mg, 18 μmol), and finally diisopropylethylamine (9.2 μL, 53 μmol). The mixture was stirred at room temperature for 1 hour. After evaporation of the solvent, water and saturated brine were added, followed by extraction with ethyl acetate. The residue was purified using a silica gel column Q-Pack SI30 size 10 (hexane:ethyl acetate = 34:66). After evaporation of the solvent, 2.2 mg (3.4 μmol, 59%) of the desired 16E (white solid) was obtained.

[0118] Example 29 (6R,9S)-1,3,6-Tribenzyl-N-(naphthalen-2-ylmethyl)-2,4,7-trioxo-1,3,4,6,7,9,10,11-octahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 1E

[0119] To a 4 ml vial containing compound 1D (6.3 mg, 9.1 μmol) prepared in Example 18, dichloromethane (0.908 ml) and trifluoroacetic acid (7.0 μl, 91 μmol) were added and stirred at room temperature for 1.5 hours. Saturated aqueous sodium bicarbonate solution was added to neutralize the mixture, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The solvent was evaporated to give 6.1 mg (9.1 μmol, 100%) of the target compound 1E (white solid).

[0120] Examples 30-34 Under the same reaction conditions as in Example 29, the five compounds shown in Table 5 were synthesized by using compounds 2D (Example 19), 4D (Example 21), 5D (Example 22), 7D (Example 24), and 8D (Example 25) instead of the starting compound 1D.

[0121]

[0122]

[0123] Preparation Examples 16 to 23 Eight compounds shown in Table 6 were synthesized under the same reaction conditions as in Preparation Example 1, except that various amine starting materials were used in place of the amine starting material, 2,5-diethyl-(2R,5S)-pyrrolidine-2,5-dicarboxylate hydrochloride, and various carboxylic acid starting materials were used in place of the carboxylic acid starting material, N-Fmoc-D-phenylalanine. However, in Preparation Examples 21, 22, and 23, a Boc-protected compound was used as the carboxylic acid starting material, and therefore, after condensation, the Boc group was removed using trifluoroacetic acid, and the compound was then treated directly with a base (triethylamine or piperidine) for cyclization.

[0124]

[0125]

[0126] Examples 35-46 Under the same reaction conditions as in Example 1, the 14 compounds shown in Table 7 were synthesized by using various synthesized diketopiperazines instead of the raw material compound 1-1 and various isocyanates instead of benzyl isocyanate.

[0127]

[0128]

[0129]

[0130]

[0131] In the table, compound 3B is a by-product obtained during the synthesis of compound 3A in Example 3.

[0132] Examples 47-52 Seven compounds shown in Table 8 were synthesized under the same reaction conditions as in Example 18, except that various synthesized triazinetrione compounds were used instead of the starting compound 1A. For Examples 47 and 48, however, compounds 20D and 21D were synthesized in one step from the carboxylic acid compounds 20C and 21C obtained in Examples 36 and 37, respectively.

[0133]

[0134]

[0135] Example 53 (6R,9R)-1,3,6-tribenzyl-N-(naphthalen-2-ylmethyl)-2,4,7-trioxo-1,2,3,4,6,7,9,10,11,12-decahydropyrido[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 25E

[0136] Example 53-1: Compound 25C Compound 25-1 (37.7 mg, 0.119 mmol) prepared in Preparation Example 20 was added to a 10 ml eggplant-shaped flask and dissolved in tetrahydrofuran (1.19 ml). Subsequently, benzyl isocyanate (45 μl, 0.358 mmol) and 60% sodium hydride in oil (42.9 mg, 1.073 mmol) were added, and the mixture was stirred at room temperature under a nitrogen atmosphere for 20 minutes. The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. After evaporation of the solvent, the residue was purified using a silica gel column (Q-Pack SI30 size 10) (hexane:ethyl acetate = 50:50 and chloroform:methanol = 95:5 to 75:25). After evaporation of the solvent, 20 mg (35 μmol, 30%) of the desired compound 25C (white amorphous solid) was obtained.

[0137] Example 53-2: Compound 25D To a 10 ml eggplant-shaped flask containing compound 25C (20 mg, 35 μmol) prepared in Example 53-1, dichloromethane (1.17 ml) was added, followed by HATU (26.7 mg, 70 μmol), 1-(2-naphthyl)methanamine (11.6 mg, 70 μmol), and finally diisopropylethylamine (36.8 μl, 0.211 mmol). The mixture was stirred at room temperature under a nitrogen atmosphere for 2.5 hours. The stir bar was removed and the solvent was evaporated. Water was added and the mixture was extracted with ethyl acetate. The residue was purified using two Q-pack SI30 size 10 silica gel columns (hexane:ethyl acetate = 60:40 to 50:50). After evaporation of the solvent, 17.6 mg (25 μmol, 71%) of the desired product 25D (white solid) was obtained.

[0138] Example 53-3: Compound of Example 53 (6R,9R)-1,3,6-tribenzyl-N-(naphthalen-2-ylmethyl)-2,4,7-trioxo-1,2,3,4,6,7,9,10,11,12-decahydropyrido[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 25E To a 4 ml vial containing compound 25D (4.2 mg, 5.9 μmol) prepared in Example 53-2, dichloromethane (0.593 ml) and trifluoroacetic acid (4.5 μl, 59.3 μmol) were added and stirred at room temperature for 1.5 hours. A saturated aqueous solution of sodium bicarbonate was added to neutralize the mixture, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The solvent was evaporated to give 4.1 mg (5.9 μmol, 100%) of the desired 25E (amorphous solid).

[0139] Example 54 (6R,9S,11aR,11bR)-6-benzyl-11b-hydroxy-N-methyl-2,4,7-trioxo-1,3-bis(thiophen-2-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 18F

[0140] Example 54-1: Compound 18C Compound 18A (13.1 mg, 22 μmol) prepared in Example 17 was added to a 4 mL vial and dissolved in tetrahydrofuran (0.232 mL), methanol (0.352 mL), and water (0.116 mL). Lithium hydroxide (23.1 mg, 0.551 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was quenched with 1 M aqueous hydrochloric acid, followed by extraction with ethyl acetate and evaporation of the solvent to obtain 12.4 mg (22 μmol, 100%) of the desired compound 18C (white solid).

[0141] Example 54-2: Compound of Example 54 (6R,9S,11aR,11bR)-6-benzyl-11b-hydroxy-N-methyl-2,4,7-trioxo-1,3-bis(thiophen-2-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 18F

[0142] To a 4 mL vial of compound 18C (7.3 mg, 12.9 μmol) prepared in Example 54-1, dichloromethane (0.368 mL) was added, followed by HATU (9.8 mg, 26 μmol), methylamine hydrochloride (2.7 mg, 39 μmol), and finally diisopropylethylamine (13.5 μL, 77 μmol). The mixture was stirred at room temperature for 1 hour. After evaporation of the solvent, saturated aqueous sodium bicarbonate was added and the mixture was extracted with ethyl acetate. The residue was purified using a silica gel column (Q-pack SI30 size 10) (hexane:ethyl acetate = 50:50 and chloroform:methanol = 100:0 to 95:5). After evaporation of the solvent, 7.1 mg (12.2 μmol, 93%) of the desired compound 18F (white solid) was obtained.

[0143] Example 55 Isopropyl (6R,9S,11aR,11bR)-6-benzyl-11b-hydroxy-2,4,7-trioxo-1,3-bis(thiophen-2-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxylate 18G and (6R,9S,11aR)-6-benzyl-N-((3-(dimethylamino)propyl)carbamoyl)-N-ethyl-11b-hydroxy-2,4,7-trioxo-1,3-bis(thiophen-2-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 18H

[0144] To a 4 ml vial of compound 18C (10 mg, 17.6 μmol) prepared in Example 54-1, dichloromethane (0.441 ml) and DMF (0.22 ml) were added, followed by DMAP (1.1 mg, 9.0 μmol), isopropanol (27.6 μl, 35.3 μmol), and EDCI (4.5 mg, 23 μmol). The mixture was stirred at room temperature for 4 hours. Since no progress was observed in the reaction, HATU (20.5 mg, 53 μmol) and diisopropylethylamine (28.2 μl, 0.159 mmol) were added and the mixture was stirred at room temperature for 2 hours. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. After evaporation of the solvent, the residue was purified on a silica gel column Q-pack SI30 size 10 (hexane:ethyl acetate = 80:20 to 50:50 and chloroform:methanol = 100:0 to 95:5). After evaporation of the solvent, 2.2 mg (3.6 μmol, 21%) of the desired compound 18G (amorphous solid) and 5.2 mg (7.2 μmol, 41%) of compound 18H (amorphous solid) were obtained.

[0145] Example 56 (6R,9S,11aR)-6-benzyl-11b-hydroxy-9-(3-methyl-1,2,4-oxadiazol-5-yl)-1,3-bis(thiophen-2-ylmethyl)hexahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-2,4,7(3H,6H)-trione

[0146] To a 4 mL vial of compound 18C (14.5 mg, 21 μmol) prepared in Example 54-1, DMF (0.417 mL) was added, followed by HATU (23.8 mg, 63 μmol) and diisopropylethylamine (32.7 μL, 0.188 mmol), and the mixture was stirred at room temperature for 8 minutes. (Z)-N'-Hydroxyacetimidamide (6.5 mg, 83 μmol) was then added, and the mixture was stirred at room temperature for 30 minutes. The reaction was quenched with saturated brine and extracted with ethyl acetate. After evaporation of the solvent, the residue was purified using a silica gel column (Q-Pack SI30 size 10) (hexane:ethyl acetate = 50:50 and chloroform:methanol = 100:0 to 95:5). After evaporation of the solvent, 9.8 mg (16 μmol, 75%) of the intermediate condensate was obtained. This was dissolved in toluene (1.57 ml) and dioxane (0.393 ml), and 4Å molecular sieves (98 mg) was added, followed by stirring for 21.5 hours at 100° C. The 4Å molecular sieves were removed by filtration while washing with chloroform. After the solvent was evaporated, the residue was purified on a silica gel column Q-pack SI30 size 10 (hexane:ethyl acetate = 75:25 to 40:60). After the solvent was evaporated, 7.4 mg (12 μmol, 78%) of the desired compound 18I (white solid) was obtained.

[0147] Example 57 (6R,9S,11aR,11bR)-N,1,3-tribenzyl-11b-hydroxy-6-isopropyl-2,4,7-trioxodecahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 3F

[0148] Example 57-1: Compound 3C Compound 3A (486.5 mg, 0.910 mmol) prepared in Example 3 was placed in a 25 ml eggplant-shaped flask and dissolved in tetrahydrofuran (2.40 ml), methanol (3.64 ml), and water (1.21 ml). Lithium hydroxide (190.9 mg, 4.55 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was quenched with 1 M aqueous hydrochloric acid, followed by extraction with ethyl acetate and evaporation of the solvent to obtain 461 mg (0.910 mmol, 100%) of the desired compound 3C (white solid).

[0149] Example 57-2: Compound of Example 57 (6R,9S,11aR,11bR)-N,1,3-tribenzyl-11b-hydroxy-6-isopropyl-2,4,7-trioxodecahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 3F

[0150] To compound 3C (20.0 mg, 39 μmol) prepared in Example 57-1 in a 10 ml eggplant-shaped flask, dichloromethane (1.32 ml) was added, followed by HATU (41.3 mg, 0.237 mmol), benzylamine (8.7 μl, 79 μmol), and finally diisopropylethylamine (41.3 μl, 0.237 mol). The mixture was stirred at room temperature for 2 hours. After evaporation of the solvent, the residue was purified using two Q-pack SI30 size 10 silica gel columns (hexane:ethyl acetate = 20:80). After evaporation of the solvent, 20.7 mg (35 μmol, 88%) of the desired compound 3F (white solid) was obtained.

[0151] Examples 58-61 Four compounds shown in Table 9 were synthesized under the same reaction conditions as in Example 57, except that various amines were used in place of benzylamine, which was the amine raw material.

[0152]

[0153]

[0154] Example 62 (6R,9S,11aR,11bR)-1,3-bis(furan-2-ylmethyl)-11b-hydroxy-6-isopropyl-2,4,7-trioxo-N-(quinolin-3-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 28F

[0155] Example 62-1: Compound 28C Compound 28A (71.9 mg, 0.140 mmol) prepared in Example 44 was added to a 25 ml eggplant-shaped flask and dissolved in tetrahydrofuran (0.368 ml), methanol (0.559 ml), and water (0.186 ml). Lithium hydroxide (58.6 mg, 1.397 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was quenched with 1 M aqueous hydrochloric acid, followed by extraction with ethyl acetate and evaporation of the solvent to obtain 68 mg (0.140 mmol, 100%) of the desired compound 28C (yellow-white solid).

[0156] Example 62-2: Compound of Example 62 (6R,9S,11aR,11bR)-1,3-bis(furan-2-ylmethyl)-11b-hydroxy-6-isopropyl-2,4,7-trioxo-N-(quinolin-3-ylmethyl)decahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-9-carboxamide 28F

[0157] To a 10-ml eggplant-shaped flask, compound 28C (20 mg, 41 μmol) prepared in Example 62-1 was added dichloromethane (1.64 ml), followed by HATU (31.3 mg, 82 μmol), C-quinolin-3-ylmethylamine dihydrochloride (28.2 mg, 0.118 mmol), and finally diisopropylethylamine (50.1 μl, 0.288 mol). The mixture was stirred at room temperature for 2 hours. After evaporation of the solvent, the residue was purified using two Q-pack SI30 size 10 silica gel columns (chloroform:methanol = 100:0 to 95:5). After evaporation of the solvent, 22.9 mg (36.5 μmol, 89%) of the desired compound 28F (white solid) was obtained.

[0158] Example 63 (6R,9S,11aR,11bR)-1,3,6-tribenzyl-11b-hydroxy-9-(((naphthalen-2-ylmethyl)amino)methyl)hexahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-2,4,7(3H,6H)-trione 1F

[0159] Example 63-1: Compound 1C-1

[0160] Compound 1C (101 mg, 0.183 mmol) prepared in Example 18-1 was placed in a 25 ml eggplant-shaped flask and dissolved in ultra-dehydrated tetrahydrofuran (1.00 ml). The mixture was cooled to 0°C, and N-methylmorpholine (29 μl, 0.260 mmol) and isobutyl chloroformate (34.8 μl, 0.260 mmol) were added. The mixture was stirred at 0°C for 30 minutes. An aqueous solution (0.70 ml) of sodium borohydride (53 mg, 1.40 mmol) was then added, followed by stirring at 0°C for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. After distilling off the solvent, the residue was purified using two connected silica gel columns, Q-pack SI30, size 20 (hexane:ethyl acetate=20:80). After distilling off the solvent, 21.9 mg (40.5 μmol, 22%) of the desired compound 1C-1 (white solid) was obtained.

[0161] Example 63-2: Compound of Example 63 (6R,9S,11aR,11bR)-1,3,6-tribenzyl-11b-hydroxy-9-(((naphthalen-2-ylmethyl)amino)methyl)hexahydro-2H-pyrrolo[2',1':3,4]pyrazino[1,2-a][1,3,5]triazine-2,4,7(3H,6H)-trione 1F

[0162] In a 4 ml vial, compound 1C-1 (7.1 mg, 13 μmol) prepared in the above Example was dissolved in dichloromethane (0.657 ml). Sodium bicarbonate (9.0 mg, 0.105 mmol) and Dess-Martin reagent (23.5 mg, 53 μmol) were added and stirred at room temperature for 45 minutes. After evaporation of the solvent, saturated aqueous sodium bicarbonate was added and the mixture was extracted with ethyl acetate. After drying over magnesium sulfate and filtration, the solvent was evaporated to obtain 7.1 mg (13 μmol, 100%) of the desired intermediate aldehyde. To this, 1-(2-naphthyl)methanamine (8.6 mg, 52 μmol) was added while washing with dichloroethane (0.80 ml), and the mixture was stirred at room temperature for 1 hour. After evaporation of the solvent, the residue was purified using two connected silica gel columns, Q-Pack SI30, size 10 (chloroform:methanol = 98:2). After evaporation of the solvent, 7.4 mg (11 μmol, 84%) of the intermediate imine was obtained. This was dissolved in dichloroethane (0.546 ml), and triacetoxyborohydride (28.9 mg, 0.110 mmol) was added and stirred at room temperature for 15 hours. The reaction was quenched with saturated aqueous sodium bicarbonate and extracted with ethyl acetate. After evaporation of the solvent, the residue was purified using CHROMATOREX DNH-30, size 10 (hexane:ethyl acetate = 90:10 to 0:100). After evaporation of the solvent, 5.4 mg (7.9 μmol, 73%) of the desired compound 1F (white solid) was obtained.

[0163] The molecular weights, 1H-NMR, [M+H] or [MH], and RT (retention time) of the compounds prepared in Examples 1 to 34 are summarized in Table 10.

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174] The molecular weights, H-NMR, [M+H] or [MH], and RT (retention time) of the compounds in Examples 35 to 63 are summarized in Table 11. Elution conditions: flow rate 0.9 mL / min, mobile phase A = 0.05% (v / v) formic acid aqueous solution, mobile phase B = 0.05% (v / v) formic acid in acetonitrile; 0-0.9 min: linear gradient A:B (95:5) - A:B (10:90), 0.9-3 min: A:B (10:90).

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185] The anti-SARS-CoV-2 activity of the compounds of the present invention was examined. Test Example 1: In Vitro Anti-SARS-CoV-2 Activity Test To evaluate the anti-SARS-CoV-2 activity of the compounds of the present invention, the positive control compound remdesivir was compared with compound 1D of the present invention. SARS-CoV-2 induces a cytopathic effect (CPE) in infected cells (Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, Huang B, Zhao L, Wang H, Zhou W, Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, Wu G, Song J, Tan W. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020 Aug 6;11(1):3910). Therefore, we performed an anti-SARS-CoV-2 activity test using CPE inhibition as an indicator. Specifically, we performed the test using the method described in Riva, L., Yuan, S., Yin, X. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113-119 (2020). https: / / doi.org / 10.1038 / s41586-020-2577-1, with minor modifications. VeroE6-TMPRSS2 cells seeded in 96-well plates were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.01 for 1 hour, washed with phosphate-buffered saline (PBS), and replaced with fresh DMEM medium containing 10 μM of each compound. Cell viability in each well was measured 3 days postinfection (dpi) using the CellTiterGlo® luminescence assay. Experiments were performed in duplicate and repeated twice for confirmation.

[0186] In the CPE inhibition assay, the positive control compound, Remdesivir, demonstrated greater than 90% CPE inhibition at 10 μM. Compound 1D, prepared in Example 19, demonstrated approximately 100% inhibitory activity, demonstrating its anti-SARS-CoV-2 activity equivalent to or superior to that of Remdesivir. For comparison, the inhibitory effect in the untreated group of virus-infected cells was 0%, while that in the uninfected group was 100%.

[0187] Test Example 2: 50% effective concentration (EC 50 Compound 1D, which showed anti-SARS-CoV-2 activity equivalent to or greater than that of the positive control compound Remdesivir in the CPE inhibition assay, was measured according to the method described in the literature as follows. 50To determine the viral load, we performed a viral load reduction assay using VeroE6-TMPRSS2 or Caco-2 at an MOI of 0.01 at 48 hours postinfection (hpi). The supernatant of the infected cells was collected for virus quantification by qRT-PCR analysis. Specifically, 100 μl of the viral supernatant was dissolved in 400 μl of Buffer AVL, and then total RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Venlo, Netherlands). SARS-CoV-2 viral load quantification was performed by real-time one-step qRT-PCR using the QuantiNova Probe RT-PCR kit (Qiagen) and the LightCycler 480 Real-Time PCR System (Roche, Rotkreuz, Switzerland). Each reaction mixture contained 10 μl of QuantiNova Probe RT-PCR Master Mix (2x), 1.2 μl of RNase-free water, 0.2 μl of QuantiNova Probe RT-Mix, 1.6 μl each of 10 μM forward and reverse primers, 0.4 μl of 10 μM probe, and 5 μl of extracted RNA template. The total volume of the reaction mixture was 20 μl. The PCR reaction was incubated at 45°C for 10 minutes for reverse transcription, 95°C for 5 minutes for denaturation, and then 45 cycles of 95°C for 5 seconds and 55°C for 30 seconds, with signal detection and measurement after each cycle after an annealing step. The primer and probe sequences used correspond to the RNA-dependent RNA polymerase / helicase (RdRP / Hel) gene region of SARS-CoV-2: forward primer: 5'-CGCATACAGTCTTRCAGGCT-3' (SEQ ID NO: 1); reverse primer: 5'-GTGTGATGTTGAWATGACATGGTC-3' (SEQ ID NO: 2); probe: 5'-FAM-TTAAGATGTGGCTTGCATACGTAGAC-IABkFQ-3' (SEQ ID NO: 3). EC 50 was calculated using GraphPad. The test was repeated three times.

[0188] Test Example 3 50% Cytotoxicity Concentration (CC 50To assess the cytotoxicity of selected compounds, the CellTiter-Glo® Luminescent Cell Viability Assay (Promega Corporation, Madison, WI, USA) was performed. Briefly, VeroE6-TMPRSS2 or Caco-2 cells (4 × 10 4 Cells (cells / well) were incubated with different concentrations of compounds for 48 hours, and then cell number was measured as ATP content in the cell lysate supernatant by the CellTiter-Glo® Luminescent Cell Viability Assay. 50 was calculated using GraphPad. The test was repeated three times.

[0189] EC in Test Examples 2 and 3 50 and CC 50 Compound 1D showed an EC 50 = 3.98 μM, CC for VeroE6-TMPRSS2 cells 50 EC = 144.7 μM against the delta strain of SARS-CoV-2 virus. 50 = 1.71uM, CC against Caco-2 cells 50 The results showed selectivity indices (CC) of approximately 36 and 234 times higher than those of the Omicron and Delta strains, respectively. 50 / EC 50 The compounds of the present invention are useful for the treatment and prevention of COVID-19.

[0190] The materials used in the above studies are as follows: Cell lines VeroE6 (ATCC CRL-1586®) and VeroE6-TMPRSS2 (BPS Bioscience Catalog #78081) and Caco-2 cells (ATCC HTB-37™) were purchased commercially and subcultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, CA, USA), 50 U / mL penicillin, and 50 μg / mL streptomycin. All antibiotics and supplements were purchased from ThermoFisher Scientific (Waltham, MA). All cell lines tested negative for mycoplasma.

[0191] The viral strains SARS-CoV-2 HKU-001a (GenBank accession number: MT230904) and SARS-CoV-2 Omicron BA.5.2 S (GISAID: EPI_ISL_13777659) and B.1.617.2 / delta (GenBank: OM212471) were isolated from nasopharyngeal aspirates of COVID-19 patients in Hong Kong. Viruses were propagated in VeroE6 cells and stored in aliquots at -80°C until use. The titer of the cultured SARS-CoV-2 was determined by plaque-forming unit (PFU) assay.

[0192] Test Example 4: In Vitro Anti-SARS-CoV-2 Viral Activity Test To evaluate the anti-SARS-CoV-2 viral activity of the compounds of the present invention other than Compound 1D, a cytopathic effect (CPE) inhibition assay was performed as described in Riva, L., Yuan, S., Yin, X. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113-119 (2020). https: / / doi.org / 10.1038 / s41586-020-2577-1, with slight modifications. VeroE6-TMPRSS2 cells seeded in a 96-well plate were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.01 for 1 hour, washed with phosphate-buffered saline (PBS), and replaced with fresh DMEM medium containing 10 μM of each compound. Cell viability in each well was measured by CellTiterGlo® luminescent assay at 3 days post infection (dpi) and averaged from three replicates.

[0193] At a compound concentration of 10 μM, compounds that showed a CPE inhibitory effect of 5% or more were rated A, compounds that showed a CPE inhibitory effect of less than 5% but 1% or more were rated B, and compounds that showed an inhibitory effect below that were rated C. For reference, the inhibitory effect in the untreated group of virus-infected cells was 0%, and that in virus-uninfected cells was 100%.

[0194]

[0195]

[0196] In a further aspect, the present invention includes the following embodiments: Compound

[101] Formula (I): wherein ring A is a group represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 together with the carbons to which they are attached are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, optionally substituted carbonyl, optionally substituted sulfonyl, or optionally substituted sulfinyl; X is hydrogen, hydroxy, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, Y is hydrogen or optionally substituted C1-6 alkyl, or X and Y together with adjacent carbon atoms form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring;wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] a compound represented by the formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof;

[0197]

[102] Formula (I): wherein ring A is a group represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7, together with the carbons to which they are attached, are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; X is hydrogen or hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y, together with the adjacent carbon atoms, form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring; wherein the substituents in "optionally substituted" are selected from the following: It is hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] The compound according to

[101] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof,

[0198]

[103] Formula (II): [wherein ring A, R1 and R7, R2 and R4, X and Y, and Z are as defined above], an enantiomer thereof, or a pharmaceutically acceptable salt thereof according to

[101] or

[102] .

[0199]

[104] Ring A is a group represented by the formula: [wherein R3, R5, R6 and R8, Y, T, U, V and W are as defined above; and Q is hydrogen, hydroxy, halogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylamino, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl]. A compound according to any one of

[101] to

[103] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, selected from the group represented by the formula:

[0200]

[105] Ring A is a group represented by the formula: [wherein R3, R5, R6 and Y are as defined above; R is hydrogen, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl]; and X is hydroxy. The compound according to

[104] , its enantiomer, or a pharmaceutically acceptable salt thereof.

[0201]

[106] The compound according to any one of

[101] to

[105] , its enantiomer, or its pharmaceutically acceptable salt, wherein R2 and R4 are the same group.

[0202] <Preferred Compound>

[107] Formula (III): wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 are joined together with the carbons to which they are attached to form a bridge to form a C3-6 spiro ring; R2 and R4 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5 and R6 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy, X is hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y together with the adjacent carbon atom form a double bond; wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.] A compound according to any of

[101] to

[106] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0203]

[108] Either R1 or R7 is hydrogen, and the other is a group of the formula: or R1 and R7 together are selected from groups of the formula: and the triazacyclohexane ring substituted with R2, R4 and X forms a spiro ring represented by the formula: The compound according to

[107] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group represented by the formula:

[0204]

[109] The compound according to

[107] or

[108] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, wherein X and Y together with the adjacent carbon atoms form a double bond.

[0205]

[110] Formula: The compound according to

[109] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, which is a compound according to any one of the following:

[0206]

[111] R3 is a group of the formula: [wherein each R9 is independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group, or when there are two R9s, they are bridged together with the nitrogen to which they are attached to form an optionally substituted 3- to 6-membered ring.] The compound according to any one of

[107] to

[110] , its enantiomer, or a pharmaceutically acceptable salt thereof,

[0207] [111-2] R3 is a group represented by the formula: [wherein R9, together with the nitrogen to which they are attached, form a bridge to form an optionally substituted 5-membered ring], the compound according to [111-2], its enantiomer, or a pharmaceutically acceptable salt thereof.

[0208] [111-3] Formula: is an optionally substituted 5-membered ring of the formula: [wherein X is hydrogen, hydroxy, halogen, cyano, carbamoyl, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, or optionally substituted C1-6 alkylamino], an enantiomer thereof, or a pharmaceutically acceptable salt thereof according to [111-2].

[0209]

[112] R3 is a group of the formula: [wherein each R9 independently represents hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group.] A compound according to any one of

[111] to [111-3], an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

[0210]

[113] R3 is a group of the formula: The compound according to

[112] , an enantiomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is a group represented by the formula:

[0211]

[114] The compound according to any one of

[107] to

[113] , its enantiomer, or its pharmaceutically acceptable salt, wherein R2 and R4 are the same group.

[0212]

[115] The compound according to any one of

[107] to

[114] , its enantiomer, or its pharmaceutically acceptable salt, wherein X and Y together with the adjacent carbon atoms form a double bond.

[0213] <Pharmaceutical Composition>

[116] A pharmaceutical composition comprising the compound according to any one of

[101] to

[115] , its enantiomer, or a pharmaceutically acceptable salt thereof.

[0214]

[117] The pharmaceutical composition described in

[116] for treating or preventing novel coronavirus infection caused by SARS-CoV-2.

[0215] The present invention is useful for treating or preventing novel coronavirus infection caused by SARS-CoV-2.

Claims

1. Formula (I): [In the formula, ring A is represented by the formula: wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 together with the carbons to which they are attached are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, optionally substituted carbonyl, optionally substituted sulfonyl, or optionally substituted sulfinyl; X is hydrogen, hydroxy, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, Y is hydrogen or optionally substituted C1-6 alkyl, or X and Y together with the adjacent carbon atoms form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring;Here, the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.], an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.; 2. Formula (I): [In the formula, ring A is represented by the formula: R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 together with the carbons to which they are attached are bridged to form a C3-6 spiro ring; R2 and R4 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; X is hydrogen or hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y together with the adjacent carbon atoms form a double bond; each Z is independently oxygen or sulfur; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5, R6 and R8 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy; T, U, V and W are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or T and U together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring, and / or V and W together with adjacent carbon atoms form a double bond or an optionally substituted benzene ring; wherein the substituents in "optionally substituted" are selected from the following: It is hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group.

2. The compound according to claim 1, wherein the compound is an enantiomer or a pharma- ceutically acceptable salt thereof.

3. Formula (II): The compound according to claim 1, which is a compound represented by the formula: [wherein ring A, R1 and R7, R2 and R4, X and Y, and Z are as defined above], its enantiomer, or its pharma- ceutically acceptable salt.

4. Ring A is of the formula: [wherein R3, R5, R6 and R8, Y, T, U, V and W are as defined above; and Q is hydrogen, hydroxy, halogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C1-6 alkylthio, optionally substituted C1-6 alkylamino, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl]. The compound of claim 1, its enantiomer, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

5. Ring A is of the formula: The compound according to claim 4, its enantiomer, or a pharma- ceutically acceptable salt thereof, wherein R is selected from the group consisting of hydrogen, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; and X is hydroxy.

6. The compound according to claim 1, its enantiomer, or a pharma- ceutically acceptable salt thereof, wherein R2 and R4 are the same group.

7. Formula (III): wherein R1 and R7 are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl, or R1 and R7 are bridged together with the carbons to which they are attached to form a C3-6 spiro ring; R2 and R4 are each independently optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, or optionally substituted C5-10 heteroaryl; R3 is optionally substituted C1-6 alkyl, optionally substituted C5-10 heteroaryl, or optionally substituted carbonyl; R5 and R6 are each independently hydrogen, hydroxy, halogen, amino, cyano, optionally substituted carbonyl, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or optionally substituted C1-6 alkoxy, X is hydroxy, Y is hydrogen or optionally substituted methyl, or X and Y together with the adjacent carbon atom form a double bond; wherein the substituent in "optionally substituted" is selected from the following: hydroxy, halogen, cyano, carbamoyl, amino, carboxy, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C6-10 aryl, optionally substituted C5-10 heteroaryl, or a protecting group. The compound according to claim 1, its enantiomer, or a pharma- ceutically acceptable salt thereof.

8. One of R1 and R7 is hydrogen and the other is a group represented by the formula: or R1 and R7 taken together are selected from the group represented by the formula: and the triazacyclohexane ring substituted with R2, R4 and X forms a spiro ring of the formula:

8. The compound according to claim 7, selected from the group consisting of:

9. The compound according to claim 7, wherein X and Y together with adjacent carbon atoms form a double bond, an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.

10. Formula:

10. The compound according to claim 9, which is any one of the compounds according to the formula:

11. R3 has the formula: [wherein R9 is independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group, or when there are two R9, they are bridged together with the nitrogen to which they are attached to form an optionally substituted 3-6 membered ring.] The compound according to claim 7, its enantiomer, or a pharma- ceutically acceptable salt thereof.

12. R3 has the formula: [wherein R9 is independently hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C6-10 aryl, an optionally substituted C5-10 heteroaryl, or a protecting group.] The compound according to claim 11, its enantiomer, or a pharma- ceutically acceptable salt thereof.

13. R3 has the formula:

13. The compound according to claim 12, which is a group represented by:

14. The compound according to claim 7, its enantiomer, or a pharma- ceutically acceptable salt thereof, wherein R2 and R4 are the same group.

15. The compound according to claim 7, wherein X and Y together with adjacent carbon atoms form a double bond, an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15, an enantiomer thereof, or a pharma- ceutically acceptable salt thereof.

17. The pharmaceutical composition according to claim 16, for treating or preventing SARS-CoV-2 novel coronavirus infection.

Citation Information

Patent Citations

  • Erroneous use prevention system for component

    JP2023076174A

  • tricyclic derivative

    JP2017527606A

  • Fused tricyclic pyridazinone compounds useful for treating orthomyxoviral infections - Patent Application 20070122999

    JP2019532033A

  • Bicyclic and tricyclic compounds

    JP2022529466A

  • Tricyclic inhibitors of influenza virus endonuclease

    WO2021195278A1